Epidemiology and natural history of cutaneous squamous cell carcinoma in recessive dystrophic epidermolysis bullosa patients: 20 years’ experience of a reference centre in Spain

• B. Castelo ^[1] ; D. Viñal ^[1] ; R. Maseda ^[2] ; L. Ostios ^[1] ; D. Sánchez ^[1] ; B. García-Salvatierra ^[3] ; M. J. Escámez ^[4] ; L. Martínez-Santamaría ^[4] ; M. Del Río ^[4] ; M. Mora-Rillo ^[5] ; Y. Vilches ^[6] ; M. J. Beato ^[7] ; J. C. López Gutiérrez ^[3] ; N. Romero ^[8] ; C. Santos ^[8] ; J. Miranda ^[1] ; R. de Lucas ^[2]
  1. [1] Department of Medical Oncology, La Paz University Hospital, Madrid
  2. [2] Department of Dermatology, La Paz University Hospital, Madrid
  3. [3] Department of Plastic Surgery, La Paz University Hospital, Madrid
  4. [4] CIBER on Rare Diseases (U714 CIBERER-ISCIII), Carlos III University, Madrid
  5. [5] Internal Medicine Department, La Paz University Hospital IdiPAZ, Madrid
  6. [6] Department of Palliative Care, La Paz University Hospital, Madrid
  7. [7] Department of Pathology, La Paz University Hospital, Madrid
  8. [8] DEBRA (Dystrophic Epidermolysis Bullosa Research Association), Madrid

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 21, Nº. 11, 2019, págs. 1573-1577
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Background Cutaneous squamous cell carcinoma (cSCC) is the leading cause of death in patients with recessive dystrophic epidermolysis bullosa (RDEB). We provide the management and prognosis of cSCC in RDEB patients at a Spanish reference center.

    Materials and methods We retrospectively included patients with RDEB attended in La Paz University Hospital from November 1988 to October 2018.

    Results Fourteen patients developed at least one cSCC. Tumors were predominantly well differentiated. Nearly half of the tumors have recurred. Median time to first recurrence was 23.4 months (95% CI: 17.2–29.5). Five patients have developed distant metastases. Median overall survival (mOS) was 136.5 months since the diagnosis of the first cSCC (95% CI: 30.6–242.3). When distant metastases occurred, mOS was 6.78 months (95% CI: 1.94–11.61).

    Conclusions cSCC is a life-threatening complication of RDEB patients. Although tumors are usually well differentiated, they tend to relapse. This is the first Spanish report of cSCC arising in RDEB patients.